EATRIS
EATRIS ERIC is a non-profit European Research Infrastructure Consortium, headquartered in Amsterdam, that provides academia, biotech SMEs, pharmaceutical companies, public funders, and policy makers with single-point access to over 175 top-tier European academic centres for translational drug, vaccine, and diagnostic development.
- Company typePrivate
- Founded2013
- HeadquartersAmsterdam, Netherlands
- Headcount101–250
- GTM typeB2B
- OfferingServices
What EATRIS does
EATRIS ERIC is a non-profit European Research Infrastructure Consortium for translational medicine, established by Commission Implementing Decision 2013/640/EU on 7 November 2013, with headquarters in Amsterdam, Netherlands. It functions as a single point of access to expertise and facilities from over 175 top-tier academic centres across 15 European countries (Bulgaria, Croatia, Czech Republic, Finland, France, Italy, Latvia, Luxembourg, Netherlands, Portugal, Slovakia, Slovenia, Spain, Sweden, and Türkiye), supporting the preclinical and early clinical development of drugs, vaccines, and diagnostics.
The offering is organised around five scientific technology platforms — ATMP (Advanced Therapy Medicinal Products), Biomarkers, Imaging & Tracing, Small Molecules, and Vaccines, Inflammation and Immune Monitoring — complemented by self-service resources such as Tracer Factory, the Innovation Helpdesk, the Innovation Management Toolbox, the Multi-omics Toolbox (MOTBX), the Orphan Drug Development Guidebook, the Patient Engagement Resource Centre, and a Regulatory Database. Service lines include Industry–Academia collaborations, support for funding applications, regulatory services, Health Technology Assessment, translational feasibility assessment, and education/training through the Transmed Academy. Quality is supported by ISO 9001, ISO 17025, and ISO 15189 accreditations across member nodes.
EATRIS's business model is that of a publicly-funded research infrastructure rather than a commercial vendor. Revenue is generated from (i) national government contributions from member countries, (ii) competitive EU project grants under programmes such as canSERV, REMEDi4ALL, ERDERA, PRECISEU, ERA4Health, EUCAIM, and EU-AMRI, and (iii) fee-for-service research activity whose proceeds are reinvested into the translational ecosystem. It serves four primary customer segments — Academia, Industry (biotech SMEs and pharmaceutical companies), Public Funding Agencies and Charities, and Policy Makers — through a mix of direct enterprise engagement, expert centres, and self-service tooling. Distribution is anchored in long-term strategic partnerships (notably with GlaxoSmithKline via an extended molecular imaging hub), EU project collaborations, and a network of national nodes.
EATRIS firmographics
Firmographics- Name
- EATRIS
- Legal name
- EATRIS ERIC
- Website
- https://eatris.eu
- Company type
- Private
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- EATRIS ERIC is a non-profit European Research Infrastructure Consortium, headquartered in Amsterdam, that provides academia, biotech SMEs, pharmaceutical companies, public funders, and policy makers with single-point access to over 175 top-tier European academic centres for translational drug, vaccine, and diagnostic development.
- Ownership category
- akta.pro rank
Where EATRIS is headquartered
LocationHeadquarters
- HQ city
- Amsterdam
- HQ country
- Netherlands
- HQ region
- Europe
Offices1 record
Markets served
EATRIS business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure
Revenue model
- Research Services: EATRIS provides a broad range of research services for both academia and industry. As a non-profit organisation, revenue generated is reinvested into supporting the translational research ecosystem. Services include industry-academia collaborations, regulatory services, innovation services, and education & training.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels5 records
EATRIS product offering
Product offeringCore offering
EATRIS is the European infrastructure for translational medicine, providing access to expertise and facilities from over 175 top-tier academic centres across 15 European countries. It offers scientific platforms (ATMP, Biomarkers, Imaging & Tracing, Small Molecules, Vaccines/Inflammation/Immune Monitoring), specialized services (regulatory, innovation, industry-academia collaborations, funding application support, health technology assessment, translational feasibility assessment), and self-service resources for drug, vaccine, and diagnostic development.
Product overview
EATRIS is the European infrastructure for translational medicine, functioning as a non-profit research organization that provides access to resources and services from over 175 top-tier academic centres across Europe. The offering consists of five scientific technology platforms (ATMP, Biomarkers, Imaging and Tracing, Small Molecules, and Vaccines/Inflammation/Immune Monitoring) that enable preclinical and early clinical development of drugs, vaccines, and diagnostics. Supporting these platforms are self-service resources including the Tracer Factory, Innovation Helpdesk, Innovation Management Toolbox, Multi-omics Toolbox (MOTBX), Orphan Drug Development Guidebook (ODDG), Patient Engagement Resource Centre, and Regulatory Database. The organization also offers specialized services spanning industry-academia collaborations, funding application support, regulatory services, health technology assessment, and translational feasibility assessment, complemented by education and training through Transmed Academy.
Differentiator
Problem solved
Functional benefit
Products and services
- ATMP (Advanced Therapy Medicinal Products) Platform
Companies that use EATRIS
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles3 records
EATRIS technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
EATRIS partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered core, flagship and minor.
- Translation TogethercoreLong-term partnership for advancing translational medicine collaboration globally. EATRIS participates as a member of this international alliance of translational medicine organizations.
- EU-AMRIcoreEuropean Alliance of Research Infrastructures working together on shared objectives including translational medicine research coordination.
- NewFoundcoreLong-term partnership focusing on rare disease research and development collaboration.
- GlaxoSmithKline (GSK) HubflagshipEATRIS and GSK extended their collaboration for three additional years, with EATRIS managing the molecular imaging hub with GSK. This partnership supports industry-academia collaborations in translational research.
- European Joint Programme on Rare Diseases (EJP RD)coreEATRIS contributes to the mentoring programme for rare disease researchers, continued in the follow-on European Rare Diseases Research Alliance (ERDERA).
- ELIXIR LuxembourgcoreLCSB hosts the national node of ELIXIR, the European infrastructure for life science information, focusing on long-term sustainability of tools and data for translational medicine.
- Health-RI (Netherlands)coreJoint initiative of Dutch nodes of EATRIS, ELIXIR, and BBMRI, along with Dutch university medical centres. Builds a National Health Research Infrastructure for personalised medicine.
- LuxinnovationminorLuxembourg innovation agency empowering companies, supporting translational projects in Luxembourg's biomedical research sector.
- Research LuxembourgminorJoint initiative of main actors in Luxembourg public research, supporting translational projects and infrastructure development.
Scale indicators2 records
Recent moves6 records
Expansion highlights6 records
EATRIS competitors and assessment
Company assessmentDirect peers
- ELIXIR: ERIC for biological data infrastructure coordinating life science data resources across Europe. Directly comparable as a sister ERIC within the EU research infrastructure ecosystem, and EATRIS already partners with ELIXIR Luxembourg for data sustainability.
- Euro-BioImaging ERIC: Pan-European research infrastructure offering open access to biological and medical imaging technologies. Overlaps directly with EATRIS's Imaging & Tracing Platform and competes/cooperates for translational imaging service contracts.
- ECRIN (European Clinical Research Infrastructure Network): ERIC-registered clinical trials infrastructure providing pan-European coordination of multinational clinical studies. Directly comparable as a fellow research infrastructure serving translational research across the EU with similar governance and funding model.
- ECRAID (European Clinical Research Alliance for Infectious Diseases): European clinical research network for infectious disease preparedness and response. Comparable as an EU-funded translational network targeting vaccine and therapeutic development, overlapping with EATRIS's VIIM Platform.
- BBMRI-ERIC: European biobanking research infrastructure providing access to biological samples and associated data. A fellow ERIC offering complementary translational infrastructure; EATRIS's Health-RI partnership already integrates BBMRI's Dutch node.
- INFRAFRONTIER: European research infrastructure for mammalian model organism phenotyping and archiving. A fellow ERIC serving preclinical translational research with similar governance structure and EU funding dependencies.
Broad incumbents
- Fraunhofer Society: Germany's largest applied research organization operating 76 institutes across multiple technology and life science domains. Comparable as a publicly-funded translational research infrastructure offering industry-facing contract research at much larger scale.
- Evotec SE: Global drug discovery and development CRO offering end-to-end services from target identification through clinical development. Comparable as a commercial alternative for biotech and pharma sponsors evaluating EATRIS for translational and early-development services.
- INSERM: France's national institute for health and medical research, operating translational research across all major therapeutic areas. Comparable as a large, publicly-funded translational research organization, though geographically focused on France.
- Charles River Laboratories: Global contract research organization offering preclinical and translational services including biomarker discovery, ATMP development support, and imaging services. Comparable as a commercial provider of overlapping capabilities EATRIS aggregates from academic partners.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
EATRIS social profiles
Digital presenceEATRIS compliance and trust
Trust signalCompliance4 records
EATRIS financial estimates
Financial estimateRevenue estimate
Valuation estimate
EATRIS leadership team
Management profileNumber of profiles
Profiles2 records
EATRIS funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
EATRIS M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about EATRIS
What does EATRIS do?
EATRIS is the European infrastructure for translational medicine, providing access to expertise and facilities from over 175 top-tier academic centres across 15 European countries. It offers scientific platforms (ATMP, Biomarkers, Imaging & Tracing, Small Molecules, Vaccines/Inflammation/Immune Monitoring), specialized services (regulatory, innovation, industry-academia collaborations, funding application support, health technology assessment, translational feasibility assessment), and self-service resources for drug, vaccine, and diagnostic development.
Is EATRIS a public or private company?
EATRIS is a private company. It is classified as nonprofit foundation owned and is currently operating.
When was EATRIS founded?
EATRIS was founded in 2013. It employs 101 to 250 people.
Where is EATRIS based?
EATRIS is headquartered in Amsterdam, Netherlands, in the Europe region.
How does EATRIS make money?
One revenue line is on record: research Services.
Who are EATRIS's main competitors?
Direct peers on record are ELIXIR, Euro-BioImaging ERIC, ECRIN (European Clinical Research Infrastructure Network), ECRAID (European Clinical Research Alliance for Infectious Diseases), BBMRI-ERIC and INFRAFRONTIER. Broad incumbents are Fraunhofer Society, Evotec SE, INSERM and Charles River Laboratories.
Does EATRIS have an API?
No public API is recorded for EATRIS.